Staar Surgical Co (NAS:STAA)

Q4 2025 STAAR Surgical Co Earnings Call Transcript

Mar 03, 2026 / 10:30PM GMT

Release Date Price: $18.92 (-0.68%)

Transcript 8-K10-K

Key Points

Positve

Staar Surgical Co (STAA) reported a significant improvement in gross profit margin for Q4 2025, reaching 75.7% compared to 64.7% in the prior year.
The company successfully reduced its annualized adjusted operating expense run rate, achieving significant cost savings in 2025.
Staar Surgical Co (STAA) launched EVO+ in China, marking the first new lens in the region in over a decade, with early demand being encouraging.
The company is expanding its commercial availability of the Lioli injector for EVO ICL procedures, enhancing its product offerings.
Staar Surgical Co (STAA) has no debt and ended the quarter with approximately $187.5 million in cash equivalents and investments available for sale.

Negative

Staar Surgical Co (STAA) faced lower than anticipated Q4 net sales due to inventory returns from China sub-distributors and customers.
The company experienced disruptions in sales due to uncertainties surrounding the proposed merger with Alcon, impacting distributor dynamics.
Operating expenses for Q4 2025 included significant costs related to the terminated merger transaction with Alcon and restructuring.
Staar Surgical Co (STAA) is not providing financial guidance for 2026, indicating uncertainty in future performance.
The company expects gross margin to be slightly lower in 2026 due to higher costs from Swiss manufacturing and increased inventory reserves.

Operator

Good day, and welcome to the STAAR Surgical Company fourth-quarter 2025 financial results conference call. (Operator Instructions)

Please note this event is being recorded. I would now like to turn the conference over to Connie Johnson, Director, Investor Relations. Please go ahead.

Connie Johnson

STAAR Surgical Co - Director, Investor Relations

Thank you, operator. Good afternoon, and thank you for joining us. On the call today are Warren Foust, Interim Co-CEO, President, and Chief Operating Officer of STAAR Surgical; and Deborah Andrews, Interim Co-CEO and Chief Financial Officer of STAAR Surgical.

Earlier today, we reported our fourth quarter and fiscal 2025 results via press release and Form 8-K. We posted our results release and shareholder letter to our Investor website at investors.staar.com. Todayâs call is scheduled for one hour and will include Q&A for publishing analysts. Webcast participants can also send questions for todayâs Q&A session to [email protected].

Before we get started, I want to remind you that during

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.